Merck Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream Processing

Darmstadt, Germany, June 14, 2022: Merck, a leading science and technology company, today announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0. More>>

FUJIFILM Irvine Scientific Acquires Exclusive License for Artificial Intelligence for IVF

The Company looks to expand the use of AI in efforts to improve IVF success

SANTA ANA, Calif., June 22, 2022: FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development, and manufacture of cell culture media and assisted reproductive technologies (ART), today announced it has exclusively licensed the intellectual property relating to artificial intelligence (AI) for image-based evaluation of human embryos to improve in-vitro fertilization (IVF) success rates. The technology was developed and patented jointly by investigators from Brigham and Women’s Hospital and Massachusetts General Hospital with expertise in artificial intelligence, biomedical engineering and IVF. Terms of the deal were not disclosed. More>>

ICON Establishes University Scholarship Programme to Provide Increased Opportunities for Underrepresented Groups to Study STEM-Related Courses

Thirty-three third level students across Ireland and the US to be supported over the next four years

Dublin, Ireland – 22 June 2022 – ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, today announces that it has established a scholarship programme to provide students from underrepresented groups increased opportunities to access third level education. More>>

H&T Presspart unveil low GWP propellant filling facility

Blackburn, UK- 22nd June 2022 – H&T Presspart’s Inhalation Product Technology Centre (IPTC) is pleased to announce the opening of our laboratory facility to support the development of sustainable metered-dose inhalers with low global warming potential (GWP) propellant. More>>

New awards celebrate innovation in sustainable pharmaceutical packaging, winners announced at Connect in Pharma

The Geneva-based inaugural Connect in Pharma event will host an awards ceremony to showcase innovations in sustainable pharmaceutical packaging

17 June 2022 / Sciad Newswire / YewMaker and Connect in Pharma announce today that the winners of the new Sustainable Medicines Packaging Awards will be announced at an in-person champagne ceremony at the Connect In Pharma event in Geneva on 14 September 2022. More>>

RSSL Reveals Strategic Rebrand

The move reflects the company’s energy, purpose and confidence as it leans into an ambitious future of strategic growth

As managing director Jacinta George explains, a new brand was the natural next stage of RSSL's evolution: “RSSL has undergone huge change over the last few years. Investment across our business in areas such as digital technology, purpose-designed labs and new services has strengthened our scientific capabilities and opened up new opportunities. It’s an exciting time for RSSL and the launch of our new brand is a vital part of this journey. Rooted in our core values, it articulates who we are as a business today and speaks directly to the needs of the industries we serve. More>>

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

LONDON, UK, 17 June 2022 – Otsuka Pharmaceutical Europe Ltd. (“Otsuka”) and H. Lundbeck A/S (“Lundbeck”) today announce that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for aripiprazole as a 2-month ready-to-use (RTU) long-acting injectable (LAI) for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole. More>>

Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom

SHORT HILLS, NJ. June 16, 2022--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19. More>>

Meeting increasing demand for storing injectable drugs – SCHOTT plans to triple ready-to-use vial production capacity in the U.S.

As a globally trusted partner for advanced drug containment and delivery solutions, SCHOTT is announcing plans to triple its vial production capacity at its site in Lebanon, PA. In doing so, the international technology company will further strengthen its business for ready-to-use (RTU) solutions, which have emerged as an often preferred drug containment alternative for high-value medications. “With our investment, we are underlining our commitment to the global pharma industry and particularly the U.S. market. Additionally, we are enhancing our regional manufacturing footprint in Lebanon, Pennsylvania, where we are proudly celebrating our site’s 30th anniversary,” said Andreas Reisse, Executive Vice President of SCHOTT Pharma. More>>

Discovery of Gene Involved in Chronic Pain Creates New Treatment Target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Chronic pain is a common issue affecting millions of people worldwide, but why some people are more prone to it and what factors lead to chronic pain are not fully understood. More>>